Skip to main
  1. Stocks
  2. Oric Pharmaceuticals
  3. Forecast
ORIC

Oric Pharmaceuticals (ORIC) Stock Forecast & Price Target

Oric Pharmaceuticals (ORIC) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 55%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ORIC Pharmaceuticals is attractive fundamentally because its pipeline offers two differentiated shots on goal: rinzimetostat in mCRPC and enozertinib in atypical EGFR NSCLC, both supported by encouraging early efficacy and manageable safety signals. The ESMO updates de-risked the story, with enozertinib showing 84% confirmed ORR and 67% intracranial ORR in a high-CNS-burden group, while rinzimetostat plus darolutamide produced a 47% PSA50 rate and encouraging rPFS trends, making the upcoming MEVPRO-1 readout a key validation event. Financially, the company’s modeled opportunity is sizable, including $1.4B peak worldwide sales for rinzimetostat in post-abiraterone mCRPC and cash runway into 2H28, which supports a positive long-term outlook despite clinical-stage risk.

Bears say

ORIC Pharmaceuticals is facing a weakening fundamental case as increasing competition in mCRPC raises the efficacy bar and makes rinzimetostat’s eventual differentiation less certain, especially while Pfizer’s MEVPRO-1 readout in 4Q26 remains the more relevant randomized test. JNJ-6143’s 77% confirmed PSA50 rate, 75% ORR, and 11.0-month median duration of response show that credible alternatives are emerging, while ORIC’s own program is still tied to earlier-stage validation in the Ph 3 Himalayas-1 study. At the same time, safety concerns persist, with Grade ≥3 treatment-related adverse events rising from 10% to 17%, one treatment-related Grade 5 acute kidney injury reported, and metabolic/hepatic toxicity signals that could complicate development and commercialization.

Oric Pharmaceuticals (ORIC) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 55% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oric Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Oric Pharmaceuticals (ORIC) Analyst Forecast & Price Prediction

Get the latest Oric Pharmaceuticals (ORIC) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Oric Pharmaceuticals (ORIC)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oric Pharmaceuticals (ORIC) Forecast

Analysts have given Oric Pharmaceuticals (ORIC) a Buy based on their latest research and market trends.

According to 11 analysts, Oric Pharmaceuticals (ORIC) has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oric Pharmaceuticals (ORIC)


Oric Pharmaceuticals (ORIC) Analyst Forecast & Price Prediction

Get the latest Oric Pharmaceuticals (ORIC) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Oric Pharmaceuticals (ORIC)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ORIC stock data and trends